•  
  •  
  •  
  •  

2025-09-03 10:00:35

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • NDTV Board approves Rights Issue of upto INR 400 Crore
  • Cupid Limited Robust B2B Export Order Book & Encouraging International Order Pipeline
  • PNC Infratech Ltd emerges L1 bidder for AAI tender
  • ITCONS E-Solutions Limited bags contract
  • SDHI & Indian Maritime University sign MoU to launch maritime Centres of Excellence, specialized workforce training programmes

Keywords Selected:  DrLalPathLabs

Stock Report

  • Dr. Lal PathLabs Pioneers AI Integration in Cancer Diagnosis in India
  • Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series
  • Dr. Lal PathLabs Limited recommends final dividend of Rs. 6
  • Dr. Lal Path Labs Ltd Q4FY25 consolidated PAT jumps to Rs. 154.8 crores
  • Dr. Lal PathLabs becomes South Asia's First Diagnostic Chain to Launch Advanced Test for Amyloidosis
  • Antara, partners with leading diagnostics player Dr. Lal PathLabs to strengthen its geriatric care services
  • Dr. Lal PathLabs Ltd Q2FY25 consolidated net profit increases to Rs. 129.2 crores
  • Dr. Lal PathLabs Limited recommends final dividend of Rs. 6
  • Dr. Lal PathLabs Ltd posts Rs. 84.5 crores consolidated PAT in Q4 FY24
  • Dr Lal Path Labs Ltd Q3FY24 consolidated net profit lower at Rs. 81.3 crores
  • Dr Lal Path Labs Ltd consolidated Q2 FY24 PAT jumps to Rs. 109.3 crores
  • Dr. Lal PathLabs Ltd approves interim dividend of Rs. 6
  • Dr. Lal Path Labs Ltd posts jump in Q1FY24 consolidated PAT to Rs. 82.6 crores
  • Dr. Lal PathLabs Ltd recommends final dividend of Rs. 6
  • Dr. Lal Path Labs Ltd reports QoQ increase in Q4FY23 consolidated net profit to Rs. 56.7 crores
  • Dr. Lal PathLabs Selects Kyndryl for Seamless Cloud Services Management
  • Dr. Lal Path Labs Ltd posts consolidated PAT of Rs. 52.9 crores in Q3FY23
  • Dr Lal Path Labs Ltd reports Rs. 71.7 crores consolidated profit in Q2FY23
  • Dr. Lal PathLabs Ltd declares interim dividend of Rs. 6
  • Dr Lal Path Labs Ltd Q1 FY2022-23 consolidated PAT lower at Rs. 57.7 crores
  • IIMA and Lal Pathlabs Foundation collaborate to set up a Research Chair in Healthcare
  • Dr. Lal Path Labs Limited recommends final dividend of Rs. 6
  • Dr. Lal Path Labs Ltd Q4FY22 consolidated net profit up QoQ at Rs. 61.3 crores
  • Dr Lal PathLabs to use drones for transport of blood samples

Latest Post

  • NDTV Board approves Rights Issue of upto INR 400 Crore
  • Cupid Limited Robust B2B Export Order Book & Encouraging International Order Pipeline
  • PNC Infratech Ltd emerges L1 bidder for AAI tender
  • ITCONS E-Solutions Limited bags contract
  • SDHI & Indian Maritime University sign MoU to launch maritime Centres of Excellence, specialized workforce training programmes


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024